ISSN: 1309 - 3843 E-ISSN: 1307 - 7384
FİZİKSEL TIP VE REHABİLİTASYON
BİLİMLERİ DERGİSİ
www.jpmrs.com
Kayıtlı İndexler


ORIJINAL ARAŞTIRMA

Kronik Nonspesifik Bel Ağrısında Dekstroz Proloterapi
Dextrose Prolotherapy Injections for Chronic Non-Specific Low Back Pain
Received Date : 23 Feb 2021
Accepted Date : 16 Aug 2021
Available Online : 24 Aug 2021
Doi: 10.31609/jpmrs.2021-82537 - Makale Dili: TR
J PMR Sci. 2022;25(1):11-9
ÖZET
Amaç: Çalışmamızda, kronik nonspesifik bel ağrılı hastalarda dekstroz proloterapinin ağrı, günlük yaşam aktiviteleri ve fonksiyonel durum üzerindeki etkilerinin belirlenmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışmamıza kronik bel ağrısı olan, geleneksel konservatif tedavi yöntemlerine yanıt vermeyen 20 hasta dâhil edildi. Lomber faset eklemlere, lomber ve sakroiliyak ligamanlara 0, 3 ve 6. haftalarda dekstroz proloterapi enjeksiyonu uygulandı. Tedavi öncesi, tedavi sonrası 1, 3, 6. ay takiplerde istirahat ve aktivite ağrı şiddeti, günlük yaşam aktiviteleri ve hasta global değerlendirme skorları sayısal derecelendirme ölçeği ile fonksiyonel durum İstanbul Bel Ağrısı Disabilite İndeksi (İBADİ) ile değerlendirildi. Bulgular: Dekstroz proloterapi uygulanan hastalarda tedavi öncesine göre tedavi sonrası 1, 3 ve 6. ayda istirahat ve aktivite ağrı şiddeti, günlük yaşam aktiviteleri, global hasta değerlendirme ölçeği ve İBADİ skorlarında anlamlı iyileşme saptandı (p˂0,001). Tedavi sonrası 1. ayda 3. aya göre değerlendirme ölçütlerinde anlamlı farklılık olmamakla beraber (p˃0,05), tedavi sonrası 6. ayda 1. aya göre aktivite ağrısı, global hasta değerlendirme skorları, günlük yaşam aktiviteleri ve İBADİ skorları anlamlı olarak düşük bulundu (p˂0,05). Sonuç: Kronik nonspesifik bel ağrısı tedavisinde dekstroz proloterapinin, ağrı, fonksiyonel durum ve günlük yaşam aktivitelerinin iyileştirilmesinde etkili olduğu ve 6 aylık takip süresince etkisinin devam ettiği saptandı. Dekstroz proloterapi, kronik nonspesifik bel ağrılı, konservatif tedaviye dirençli olan hastalarda etkin, güvenli ve ekonomik bir tedavi seçeneği olarak önerilebilir.
ABSTRACT
Objective: The aim of this study is to evaluate the effects of dextrose prolotherapy on pain, activities of daily living and disability in patients with chronic non-specific low back pain. Material and Methods: Twenty patients with chronic non-specific low back pain refractory to conservative therapy were included in this study. The dextrose prolotherapy injections were administered to lumbar facet joints, lumbar and sacroiliac ligaments, respectively, at 0, 3, and 6 weeks. Level of activity and rest pain, activities of daily living and patient global assessment measured using a numeric rating scale, and the disabiliy level measured using the İstanbul Low Back Pain Disability Index (ILBPDI) were recorded at the baseline, and at 1, 3 and 6 months. Results: The rest pain, activity pain, activities of daily living, patient global assessment scale and ILBPDI scores were significantly improved at 1, 3 and 6 months compared to the pre-treatment values (p˂0.001). There was no significant difference with regard to all outcome measures in the third month scores when compared to the first month (p˃0.05). However, the activity pain, activities of daily living, patient global assessment scale and ILBPDI scores were significantly decreased at 6-month follow up when compared to 1-month follow up (p<0,05). Conclusion: Dextrose prolotherapy appears to be an effective method for relieving pain and in improving functions and activities of daily living for treating chronic non-specific low back pain over the six months period. Dextrose prolotherapy can be recommended as an effective, safe and economical treatment option for patients with chronic non-specific low back pain refractory to conservative therapy.
REFERENCES
  1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743-800. [PubMed]  [PMC] 
  2. Hoy D, March L, Brooks P, et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:968-74. [Crossref]  [PubMed] 
  3. Maher C, Underwood M, Buchbinder R. Nonspecific low back pain. Lancet. 2017;389:736-47. [Crossref]  [PubMed] 
  4. Hartvigsen J, Hancock MJ, Kongsted A, et al. Lancet low back pain series working group. What low back pain is and why we need to pay attention. Lancet. 2018;391:2356-67. [Crossref]  [PubMed] 
  5. Hooper RA, Ding M. Retrospective case series on patients with chronic spinal pain treated with dextrose prolotherapy. J Altern Complement Med. 2004;10:670-4. [Crossref]  [PubMed] 
  6. Hackett GS, Hemwall GA, Montgomery GA. Ligament and Tendon Relaxation Treated by Prolotherapy. 5th ed. Oak Park, Illinois: Gustav A. Hemwall; 1993.
  7. Frank C, Amiel D, Woo SL, et al. Normal ligament properties and ligament healing. Clin Orthop Relat Res. 1985;15-25. [Crossref]  [PubMed] 
  8. Borenstein DG. Chronic low back pain. Rheum Dis Clin North Am. 1996;22:439-56. [Crossref]  [PubMed] 
  9. Alderman D. Prolotherapy for musculoskeletal pain. Pract Pain Manag. 2007:10-5. [Link] 
  10. Hauser RA, Lackner JB, Steilen-Matias D, et al. A systematic review of dextrose prolotherapy for chronic musculoskeletal pain. Clin Med Insights Arthritis Musculoskelet Disord. 2016;9:139-59. [Crossref]  [PubMed]  [PMC] 
  11. Reeves KD, Sit RW, Rabago DP. Dextrose prolotherapy: A narrative review of basic science, clinical research, and best treatment recommendations. Phys Med Rehabil Clin N Am. 2016;27:783-823. [Crossref]  [PubMed] 
  12. Jensen KT, Rabago DP, Best TM, et al. Early inflammatory response of knee ligaments to prolotherapy in a rat model. J Orthop Res. 2008;26:816-23. [Crossref]  [PubMed]  [PMC] 
  13. Kim HJ, Kim SH, Yun DH, et al. The effects of anti-inflammatory drugs on histologic findings of the experimental prolotherapy model. J Korean Acad Rehabil Med. 2006;30:378-84. [Link] 
  14. Güran Ş, çoban ZD, Karasimav Ö, et al. Dextrose solution used for prolotherapy decreases cell viability and increases gene expressions of angiogenic and apopitotic factors. Gulhane Med J. 2018;60:42-6. [Crossref] 
  15. Wheaton MT, Jensen N. The ligament injuryosteoarthritis connection: The role of prolotherapy in ligament repair and the prevention of osteoarthritis. J Prolotherapy. 2011;3:790-812. [Link] 
  16. Yelland MJ, Mar C, Pirozzo S, et al. Prolotherapy injections for chronic low-back pain. Cochrane Database Syst Rev. 2004 CD004059. Update in: Cochrane Database Syst Rev. 2007;CD004059. [Crossref]  [PubMed]  [PMC] 
  17. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14:798-804. [Crossref]  [PubMed] 
  18. Duruöz MT, Özcan E, Ketenci A, et al. Development and validation of a functional disability index for chronic low back pain. J Back Musculoskelet Rehabil. 2013;26:45-54. [Crossref]  [PubMed] 
  19. Yelland MJ, Glasziou PP, Bogduk N, et al. Prolotherapy injections, saline injections, and exercises for chronic low-back pain: a randomized trial. Spine (Phila Pa 1976). 2004;29:9-16; discussion 16. [Crossref]  [PubMed] 
  20. Dagenais S, Yelland MJ, Del Mar C, et al. Prolotherapy injections for chronic low-back pain. Cochrane Database Syst Rev. 2007; 2007:CD004059. [Crossref]  [PubMed]  [PMC] 
  21. Hooper RA, Yelland M, Fonstad P, et al. Prospective case series of litigants and non-litigants with chronic spinal pain treated with dextrose prolotherapy. Int Musculoskelet Med. 2011;33:15-20. [Crossref] 
  22. Maniquis-Smigel L, Dean Reeves K, Jeffrey Rosen H, et al. Short term analgesic effects of 5% dextrose epidural injections for chronic low back pain: A randomized controlled trial. Anesth Pain Med. 2016;7:e42550. [Crossref]  [PubMed]  [PMC] 
  23. Maniquis-Smigel L, Reeves KD, Rosen HJ, et al. Analgesic effect and potential cumulative benefit from caudal epidural D5W in consecutive participants with chronic low-back and buttock/leg pain. J Altern Complement Med. 2018;24:1189-96. [Crossref]  [PubMed]  [PMC] 
  24. Solmaz İ, Akpancar S, Örsçelik A, et al. Dextrose injections for failed back surgery syndrome: a consecutive case series. Eur Spine J. 2019;28:1610-7. [Crossref]  [PubMed] 
  25. Rabago D, Nourani B. Prolotherapy for osteoarthritis and tendinopathy: A descriptive review. Curr Rheumatol Rep. 2017;19:34. [Crossref]  [PubMed] 
  26. Kim WM, Lee HG, Jeong CW, et al. A randomized controlled trial of intra-articular prolotherapy versus steroid injection for sacroiliac joint pain. J Altern Complement Med. 2010;16:1285-90. [Crossref]  [PubMed] 
  27. Cusi M, Saunders J, Hungerford B, et al. The use of prolotherapy in the sacroiliac joint. Br J Sports Med. 2010;44:100-4. [Crossref]  [PubMed] 
  28. Zhang W, Robertson J, Jones AC, et al. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67: 1716-23. [Crossref]  [PubMed] 
  29. Rabago D, Reeves KD, Doherty MP, et al. Prolotherapy for Musculoskeletal Pain and Disability in Low- and Middle-Income Countries. Phys Med Rehabil Clin N Am. 2019;30:775-86. [Crossref]  [PubMed] 
  30. Beinart NA, Goodchild CE, Weinman JA, et al. Individual and intervention-related factors associated with adherence to home exercise in chronic low back pain: a systematic review. Spine J. 2013;13:1940-50. [Crossref]  [PubMed] 
  31. Saner J, Bergman EM, de Bie RA, et al. Low back pain patients' perspectives on long-term adherence to home-based exercise programmes in physiotherapy. Musculoskelet Sci Pract. 2018;38:77-82. [Crossref]  [PubMed]